Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).

Warner ET, Ballman KV, Strand C, Boughey JC, Buzdar AU, Carey LA, Sikov WM, Partridge AH.

Breast Cancer Res Treat. 2016 Aug;159(1):109-18. doi: 10.1007/s10549-016-3918-5. Epub 2016 Jul 22.

PMID:
27449492
2.

Metabolic syndrome and pre-diabetes contribute to racial disparities in breast cancer outcomes: hypothesis and proposed pathways.

Gallagher EJ, LeRoith D, Franco R, Antoniou IM, Nayak A, Livaudais-Toman J, Bickell NA.

Diabetes Metab Res Rev. 2016 Oct;32(7):745-753. doi: 10.1002/dmrr.2795. Epub 2016 Apr 21.

3.

Use of Insulin and Mortality from Breast Cancer among Taiwanese Women with Diabetes.

Tseng CH.

J Diabetes Res. 2015;2015:678756. doi: 10.1155/2015/678756. Epub 2015 Jun 11.

4.

Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.

Gallagher EJ, LeRoith D.

Physiol Rev. 2015 Jul;95(3):727-48. doi: 10.1152/physrev.00030.2014. Review.

5.

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE.

J Clin Oncol. 2015 Jul 20;33(21):2353-60. doi: 10.1200/JCO.2015.60.9271. Epub 2015 Jun 15.

6.

The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.

Bowers LW, Rossi EL, O'Flanagan CH, deGraffenried LA, Hursting SD.

Front Endocrinol (Lausanne). 2015 May 15;6:77. doi: 10.3389/fendo.2015.00077. eCollection 2015. Review.

7.

Recent advances in the use of metformin: can treating diabetes prevent breast cancer?

Hatoum D, McGowan EM.

Biomed Res Int. 2015;2015:548436. doi: 10.1155/2015/548436. Epub 2015 Mar 19. Review.

8.

Metabolic syndrome in breast cancer.

Vargas-Hernández VM, Vargas-Aguilar V, Moreno-Eutimio MA, Acosta-Altamirano G, Tovar-Rodriguez J.

Gland Surg. 2013 May;2(2):80-90. doi: 10.3978/j.issn.2227-684X.2013.04.02. Review.

9.

The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice.

Kuno T, Hata K, Takamatsu M, Hara A, Hirose Y, Takahashi S, Imaida K, Tanaka T.

Int J Mol Sci. 2014 May 22;15(5):9160-72. doi: 10.3390/ijms15059160.

10.

A Community-Based Exercise and Support Group Program in African-American Breast Cancer Survivors (ABCs).

Nock NL, Owusu C, Kullman EL, Austin K, Roth B, Cerne S, Harmon C, Moore H, Vargo M, Hergenroeder P, Malone H, Rocco M, Tracy R, Lazarus HM, Kirwan JP, Heyman E, Berger NA.

J Phys Ther Health Promot. 2013 Dec 1;1(1):15-24.

11.
12.

Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.

Sini V, Lunardi G, Cirillo M, Turazza M, Bighin C, Giraudi S, Levaggi A, Piccioli P, Bisagni G, Gnoni R, Stridi G, Porpiglia M, Picardo E, Ponzone R, Marenco D, Mansutti M, Puglisi F, Del Mastro L.

Br J Cancer. 2014 Mar 4;110(5):1133-8. doi: 10.1038/bjc.2014.2. Epub 2014 Jan 21.

13.

A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors.

Westley RL, May FE.

Int J Endocrinol. 2013;2013:632461. doi: 10.1155/2013/632461. Epub 2013 Jul 31.

14.

Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?

Holly JM, Zeng L, Perks CM.

Cancer Metastasis Rev. 2013 Dec;32(3-4):673-705. doi: 10.1007/s10555-013-9445-5. Review.

15.

Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer.

Gallagher EJ, LeRoith D.

Diabetes Care. 2013 Aug;36 Suppl 2:S233-9. doi: 10.2337/dcS13-2001. Review. No abstract available.

16.

Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer.

Ferguson RD, Gallagher EJ, Cohen D, Tobin-Hess A, Alikhani N, Novosyadlyy R, Haddad N, Yakar S, LeRoith D.

Endocr Relat Cancer. 2013 May 21;20(3):391-401. doi: 10.1530/ERC-12-0333. Print 2013 Jun.

17.

Association of serum C-peptide concentrations with cancer mortality risk in pre-diabetes or undiagnosed diabetes.

Hsu CN, Chang CH, Lin YS, Lin JW, Caffrey JL.

PLoS One. 2013;8(2):e55625. doi: 10.1371/journal.pone.0055625. Epub 2013 Feb 6.

18.

Fasting serum C-peptide levels predict cardiovascular and overall death in nondiabetic adults.

Patel N, Taveira TH, Choudhary G, Whitlatch H, Wu WC.

J Am Heart Assoc. 2012 Dec;1(6):e003152. doi: 10.1161/JAHA.112.003152. Epub 2012 Dec 19.

19.

Insulin therapy and cancer in type 2 diabetes.

Mannucci E.

ISRN Endocrinol. 2012;2012:240634. doi: 10.5402/2012/240634. Epub 2012 Nov 14.

20.

C-peptide levels are associated with mortality and cardiovascular mortality in patients undergoing angiography: the LURIC study.

Marx N, Silbernagel G, Brandenburg V, Burgmaier M, Kleber ME, Grammer TB, Winkelmann BR, Boehm BO, März W.

Diabetes Care. 2013 Mar;36(3):708-14. doi: 10.2337/dc12-1211. Epub 2012 Nov 30.

Supplemental Content

Support Center